← Back to Search

Corticosteroid

Ixazomib + Dexamethasone vs. Triple Therapy for Multiple Myeloma

Atlanta, GA
Phase 2
Waitlist Available
Led By Leon Bernal-Mizrachi, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have confirmed relapsed or refractory MM
Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2
Must not have
Female patients who are breast feeding or have a positive serum pregnancy test during the screening period
Refractory to carfilzomib or bortezomib
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the date of first dose of study treatment to the date of the first documentation of a confirmed response, assessed up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying how well ixazomib and dexamethasone or ixazomib, dexamethasone, and lenalidomide work in treating patients with multiple myeloma.

See full description
Who is the study for?
This trial is for patients with multiple myeloma that has come back or isn't responding to treatment. They must have measurable disease, be in fair health (ECOG 0-2), meet certain blood and biochemical criteria, and not be pregnant or breastfeeding. Participants should have had 1-3 prior treatments but can't join if they've used experimental proteasome inhibitors recently or haven't recovered from previous chemo.Check my eligibility
What is being tested?
The study compares two drug combinations: Ixazomib with Dexamethasone versus Ixazomib, Dexamethasone, and Lenalidomide. It's looking at how well these work based on a gene rearrangement called NFKB2 in the cancer cells. The goal is to see which combination is more effective for treating multiple myeloma.See study design
What are the potential side effects?
Possible side effects include reactions related to immune system stimulation by Lenalidomide, such as blood clots and bone marrow suppression leading to low blood cell counts. Ixazomib may cause gastrointestinal issues like nausea and skin rash, while Dexamethasone can lead to increased appetite, mood changes, and trouble sleeping.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My multiple myeloma has returned or is not responding to treatment.
 show original
Select...
I can take care of myself and am up and about more than half of my waking hours.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently breastfeeding or have tested positive for pregnancy.
 show original
Select...
My condition did not improve with carfilzomib or bortezomib treatment.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the date of first dose of study treatment to the date of the first documentation of a confirmed response, assessed up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the date of first dose of study treatment to the date of the first documentation of a confirmed response, assessed up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Response rate of very good partial response (VGPR) or better
Secondary study objectives
Duration of response (DOR)
Incidence of adverse events
Overall response rate (CR + VGPR + partial response [PR]), stable disease or progression
+1 more
Other study objectives
Gene expression profile
Transcribed mutations via RNA-sequencing

Side effects data

From 2021 Phase 4 trial • 45 Patients • NCT03416374
26%
Diarrhoea
23%
White blood cell count decreased
21%
Platelet count decreased
15%
Neutrophil count decreased
13%
Pneumonia
8%
Anaemia
8%
Constipation
8%
Malaise
8%
Pyrexia
8%
Rash
5%
Acute kidney injury
5%
Nasopharyngitis
5%
Influenza
3%
Duodenal ulcer
3%
Enterocolitis
3%
Bile duct stone
3%
Tumour lysis syndrome
3%
Interstitial lung disease
3%
Taste disorder
3%
Febrile neutropenia
3%
Prinzmetal angina
3%
Gastroenteritis
3%
Pneumonia bacterial
100%
80%
60%
40%
20%
0%
Study treatment Arm
[KRd]; Carfilzomib + Lenalidomide + Dexamethasone Therapy
[Overall]; Combination Therapy + Ixazomib Therapy
[VRd]; Bortezomib + Lenalidomide + Dexamethasone Therapy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm C (ixazomib, dexamethasone, lenalidomide)Experimental Treatment3 Interventions
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
Group II: Arm B (ixazomib and dexamethasone)Experimental Treatment2 Interventions
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
Group III: Arm A (ixazomib and dexamethasone)Active Control2 Interventions
UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
2007
Completed Phase 4
~2650
Ixazomib
2017
Completed Phase 4
~3510
Lenalidomide
2005
Completed Phase 3
~2240

Find a Location

Closest Location:University of Michigan/Rogel Cancer Center· Ann Arbor, MI· 166 miles

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,893 Previous Clinical Trials
8,051,871 Total Patients Enrolled
16 Trials studying Multiple Myeloma
854 Patients Enrolled for Multiple Myeloma
Millennium Pharmaceuticals, Inc.Industry Sponsor
405 Previous Clinical Trials
46,794 Total Patients Enrolled
82 Trials studying Multiple Myeloma
9,927 Patients Enrolled for Multiple Myeloma
Emory UniversityLead Sponsor
1,732 Previous Clinical Trials
2,606,855 Total Patients Enrolled
27 Trials studying Multiple Myeloma
1,873 Patients Enrolled for Multiple Myeloma
National Cancer Institute (NCI)NIH
14,068 Previous Clinical Trials
41,160,031 Total Patients Enrolled
596 Trials studying Multiple Myeloma
191,847 Patients Enrolled for Multiple Myeloma
Multiple Myeloma Research ConsortiumNETWORK
20 Previous Clinical Trials
1,132 Total Patients Enrolled
19 Trials studying Multiple Myeloma
1,079 Patients Enrolled for Multiple Myeloma
Leon Bernal-Mizrachi, MDPrincipal Investigator - Emory University/Winship Cancer Institute
Emory University

Media Library

Dexamethasone (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT02765854 — Phase 2
Multiple Myeloma Research Study Groups: Arm B (ixazomib and dexamethasone), Arm A (ixazomib and dexamethasone), Arm C (ixazomib, dexamethasone, lenalidomide)
Multiple Myeloma Clinical Trial 2023: Dexamethasone Highlights & Side Effects. Trial Name: NCT02765854 — Phase 2
Dexamethasone (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02765854 — Phase 2
~8 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top